COVID-19 outcomes in Rituximab treated patients Rituximab Coronavirus Disease COVID TheLancetRheum UniversityLeeds
By Dr. Liji Thomas, MDJan 11 2023Reviewed by Aimee Molineux Rituximab-treated patients with autoimmune diseases have been reported to have reduced immunogenicity for COVID-19 vaccines. There is, however, limited data on the incidence and severity of breakthrough infections among patients with specific rheumatic and musculoskeletal diseases.
The current study, published in The Lancet Rheumatology, has a retrospective design. It followed a single cohort of patients with certain autoimmune diseases who were on rituximab, taking at least one infusion between September 1, 2019, and April 1, 2022. The study period thus began six months before the pandemic.
Antibodies eBook Compilation of the top interviews, articles, and news in the last year. Download a free copy Over the 774·6 patient-years of follow-up, COVID-19 cases gradually increased across all severity phenotypes over the various waves of the pandemic. However, the rates of severe disease remained stable across waves caused by wild-type, Alpha, Delta, and Omicron variants.
Interestingly, this was similar to the rates of other severe infections in the whole group at 6 per 100 PY and to those in immunocompromised individuals.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Study explores incidence, severity, and long COVID associations of SARS-CoV-2 reinfectionsResearchers used electronic health records to characterize the incidence, biomarkers, attributes, and severity of SARS-CoV-2 reinfections and evaluated the association between reinfections and long coronavirus disease (COVID).
続きを読む »
Profound immune escape by SARS-CoV-2 XBB.1 even after 4 vaccine dosesIn a recent correspondence published in The Lancet Infectious Diseases journal, researchers in Germany assessed the neutralization sensitivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) XBB.1 lineage.
続きを読む »
Real-world effectiveness of the bivalent vaccine for preventing COVID-19 hospitalizations in non-hospitalized subjectsReal-world effectiveness of the bivalent vaccine for preventing COVID-19 hospitalizations in non-hospitalized subjects covid coronavirus covid hospital vaccine vaccination
続きを読む »
Immunomodulatory fecal metabolites are associated with mortality in COVID-19 patients with respiratory failure - Nature CommunicationsHere, via applying metagenomics and metabolomics analyses, the authors show that fecal microbiota composition and microbiota-derived metabolites predict the trajectory of respiratory function and death in patients with severe SARS-Cov-2 infection, suggesting the gut-lung axis to play an important role in the recovery from COVID-19.
続きを読む »
Spike protein mutations in Omicron subvariants increase their susceptibility to reductive cleavage of disulfide bondsResearchers discovered that the spike protein of SARS-CoV-2 is susceptible to cleavage at the disulfide bonds, and the vulnerability to reductive cleavage varies across variants, with the Omicron variant family being highly susceptible to reduction.
続きを読む »
China reopens borders after three years of Covid closureThe move follows years of Covid closure and comes as a huge travel surge begins for Lunar New Year.
続きを読む »